Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
Immunome submitted an NDA to the FDA for varegacestat in desmoid tumors after the Phase 3 RINGSIDE trial showed an 84% reduction in progression risk (HR=0.16) and a 56% objective response rate. The company plans to file in Q2 2026.
The US pharmaceutical drug delivery market is projected to rise from USD 0.94 billion in 2026 to USD 1.24 billion by 2031 at a 5.8% CAGR. Injectables, oncology applications, and home care settings are expected to post the fastest growth.
VYLOY (zolbetuximab-clzb) remains the only approved CLDN18.2-targeted therapy for first-line HER2-negative gastric or gastroesophageal junction adenocarcinoma with CLDN18.2-positive tumors. The pipeline is focused on next-generation antibodies, ADCs, CAR-T, NK-cell and bispecific approaches aiming to build on zolbetuximab benchmark data.
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
Biopharma companies face a $275b patent cliff as licensing activity shifts toward China. China represented almost half of 2025 licensing activity and contributes about 30% of the global biotech pipeline.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
University of Missouri researchers released PSBench, a database of 1.4 million annotated protein structure models verified by independent experts. The resource aims to improve AI assessment of protein models as biologic drug discovery moves toward data-driven design.
Champions Oncology said it will present eight poster presentations at AACR 2026 in San Diego on April 17-22. The studies cover KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, ADCs and CAR-T therapies.
ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.
